BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 31249568)

  • 1. FCGR3A and FCGR2A Genotypes Differentially Impact Allograft Rejection and Patients' Survival After Lung Transplant.
    Paul P; Pedini P; Lyonnet L; Di Cristofaro J; Loundou A; Pelardy M; Basire A; Dignat-George F; Chiaroni J; Thomas P; Reynaud-Gaubert M; Picard C
    Front Immunol; 2019; 10():1208. PubMed ID: 31249568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic and Functional Profiling of CD16-Dependent Natural Killer Activation Identifies Patients at Higher Risk of Cardiac Allograft Vasculopathy.
    Paul P; Picard C; Sampol E; Lyonnet L; Di Cristofaro J; Paul-Delvaux L; Lano G; Nicolino-Brunet C; Ravis E; Collart F; Dignat-George F; Dussol B; Sabatier F; Mouly-Bandini A
    Circulation; 2018 Mar; 137(10):1049-1059. PubMed ID: 29097449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection.
    Litjens N; Peeters A; Gestel JK; Klepper M; Betjes M
    Sci Rep; 2021 Apr; 11(1):7903. PubMed ID: 33846428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation.
    Arnold ML; Kainz A; Hidalgo LG; Eskandary F; Kozakowski N; Wahrmann M; Haslacher H; Oberbauer R; Heilos A; Spriewald BM; Halloran PF; Böhmig GA
    Am J Transplant; 2018 Sep; 18(9):2261-2273. PubMed ID: 29478298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional Fc Gamma Receptor Gene Polymorphisms and Long-Term Kidney Allograft Survival.
    Wahrmann M; Döhler B; Arnold ML; Scherer S; Mayer KA; Haindl S; Haslacher H; Böhmig GA; Süsal C
    Front Immunol; 2021; 12():724331. PubMed ID: 34497614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
    Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
    J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of a coding polymorphism in Fc gamma receptor 2A and graft survival in re-transplant candidates.
    Arnold ML; Fuernrohr BG; Weiß KM; Harre U; Wiesener MS; Spriewald BM
    Hum Immunol; 2015 Oct; 76(10):759-64. PubMed ID: 26429312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of Killer Immunoglobulin-like Receptor (KIR) and HLA Genotypes to Predict the Occurrence of Acute Allograft Rejection after Kidney Transplantation.
    Jafari D; Nafar M; Yekaninejad MS; Abdolvahabi R; Lesan Pezeshki M; Razaghi E; Amirzargar AA
    Iran J Allergy Asthma Immunol; 2017 Jun; 16(3):245-255. PubMed ID: 28732438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement-Activating Anti-HLA Antibodies in Kidney Transplantation: Allograft Gene Expression Profiling and Response to Treatment.
    Lefaucheur C; Viglietti D; Hidalgo LG; Ratner LE; Bagnasco SM; Batal I; Aubert O; Orandi BJ; Oppenheimer F; Bestard O; Rigotti P; Reisaeter AV; Kamar N; Lebranchu Y; Duong Van Huyen JP; Bruneval P; Glotz D; Legendre C; Empana JP; Jouven X; Segev DL; Montgomery RA; Zeevi A; Halloran PF; Loupy A
    J Am Soc Nephrol; 2018 Feb; 29(2):620-635. PubMed ID: 29042454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease.
    Rohatgi S; Gohil S; Kuniholm MH; Schultz H; Dufaud C; Armour KL; Badri S; Mailliard RB; Pirofski LA
    mBio; 2013 Aug; 4(5):e00573-13. PubMed ID: 23982074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD16
    Calabrese DR; Chong T; Singer JP; Rajalingam R; Hays SR; Kukreja J; Leard L; Golden JA; Lanier LL; Greenland JR
    Am J Transplant; 2023 Jan; 23(1):37-44. PubMed ID: 36695619
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients.
    Das LK; Ide K; Tanaka A; Morimoto H; Shimizu S; Tanimine N; Tanaka Y; Ohdan H
    Hum Immunol; 2017 Apr; 78(4):357-362. PubMed ID: 28315348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fc-Gamma Receptor Polymorphisms Predispose Patients to Infectious Complications After Liver Transplantation.
    Shimizu S; Tanaka Y; Tazawa H; Verma S; Onoe T; Ishiyama K; Ohira M; Ide K; Ohdan H
    Am J Transplant; 2016 Feb; 16(2):625-33. PubMed ID: 26517570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
    Shepshelovich D; Townsend AR; Espin-Garcia O; Latifovic L; O'Callaghan CJ; Jonker DJ; Tu D; Chen E; Morgen E; Price TJ; Shapiro J; Siu LL; Kubo M; Dobrovic A; Ratain MJ; Xu W; Mushiroda T; Liu G
    Cancer Med; 2018 Nov; 7(11):5478-5487. PubMed ID: 30318772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Lung Transplantation in the Presence of Donor-Specific Antibodies.
    Courtwright AM; Cao S; Wood I; Mallidi HR; Kawasawa J; Moniodis A; Ng J; El-Chemaly S; Goldberg HJ
    Ann Am Thorac Soc; 2019 Sep; 16(9):1131-1137. PubMed ID: 31026404
    [No Abstract]   [Full Text] [Related]  

  • 16. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
    Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
    Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection.
    Sablik KA; Litjens NHR; Klepper M; Betjes MGH
    Transpl Immunol; 2019 Jun; 54():52-58. PubMed ID: 30794946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of complement binding assays to assess the efficacy of antibody mediated rejection therapy and prediction of graft survival in kidney transplantation.
    Ramon DS; Huang Y; Zhao L; Rendulic T; Park JM; Sung RS; Samaniego M
    Hum Immunol; 2017 Feb; 78(2):57-63. PubMed ID: 27894836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
    Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
    J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.
    Morgan AW; Robinson JI; Barrett JH; Martin J; Walker A; Babbage SJ; Ollier WE; Gonzalez-Gay MA; Isaacs JD
    Arthritis Res Ther; 2006; 8(4):R109. PubMed ID: 16846526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.